Quizartinib (Vanflyta): FLT3-ITD AML Treatment Guide

Category: Blog
Author: Razu

Key Takeaways

Quizartinib (Vanflyta) is a FLT3 tyrosine kinase inhibitor approved for adult patients with newly diagnosed FLT3-ITD-positive acute myeloid leukemia (AML), a molecular subtype occurring in approximately 25–30% of newly diagnosed adult AML cases.
Quizar, manufactured by Everest Pharmaceuticals Ltd., is the Bangladeshi-manufactured brand of quizartinib available through our supply network, formulated as a 17.7 mg oral tablet.
Quizartinib carries a significant cardiac risk profile — it prolongs the QT interval in a concentration-related manner, with serious risks including torsades de pointes and cardiac arrest. Structured ECG monitoring is required throughout treatment.
The drug is contraindicated in patients with severe hypokalemia, severe hypomagnesemia, or long QT syndrome, and electrolyte deficiencies must be corrected before and during treatment.
For patients proceeding to hematopoietic stem cell transplantation (HSCT), quizartinib must be stopped 7 days before starting a conditioning regimen.
European procurement teams sourcing Quizar should verify local regulatory authorization requirements and initiate early dialogue with our supply team regarding import documentation, lead times, and availability.

What Is Quizartinib and What Disease Does It Treat?

Quizartinib (marketed globally as Vanflyta) is a targeted tyrosine kinase inhibitor specifically designed to inhibit FLT3, a receptor tyrosine kinase that is frequently mutated in acute myeloid leukemia (AML). It is approved for the treatment of adult patients with newly diagnosed AML that is FLT3 internal tandem duplication (ITD) positive — a molecular subtype associated with aggressive disease behavior and historically poor outcomes with standard chemotherapy alone.

Quizar (Everest Pharmaceuticals Ltd.) is the Bangladeshi-manufactured brand of quizartinib available through our supply network. Quizar is formulated as a 17.7 mg oral tablet and is indicated for use in combination with standard induction and consolidation chemotherapy, followed by single-agent maintenance therapy in eligible adults.

For B2B procurement teams, hospital formulary managers, and international pharmaceutical wholesalers, Quizar represents a clinically significant targeted oncology agent addressing a well-defined molecular patient population within the AML treatment landscape. The approval of quizartinib reflects advances in precision oncology, where molecular diagnostics guide therapeutic selection for improved patient outcomes in genetically defined malignancies.

Mechanism of Action: How Quizartinib Inhibits FLT3

Quizartinib is a small molecule inhibitor of the receptor tyrosine kinase FLT3. It exerts its pharmacological effect by binding directly to the ATP-binding domain of the FLT3 receptor, thereby inhibiting FLT3 kinase activity. This binding prevents the autophosphorylation and downstream signaling that FLT3-ITD mutations drive in leukemic blast cells.

In FLT3-ITD-positive AML, the internal tandem duplication mutation causes constitutive, ligand-independent activation of the FLT3 receptor. This persistent activation promotes uncontrolled proliferation and survival of malignant myeloid progenitor cells. By occupying the ATP-binding pocket, quizartinib competitively blocks this oncogenic signaling cascade, suppressing FLT3-ITD-dependent cell proliferation and inducing apoptosis in malignant cells.

Clinical Pharmacology Context

For procurement professionals asking what class of drug is quizartinib — it belongs to the tyrosine kinase inhibitor (TKI) class, specifically targeting FLT3. This positions it within the broader category of small molecule receptor tyrosine kinase inhibitors used in molecularly targeted oncology, a class that has substantially expanded treatment options for genetically defined hematologic malignancies over the past two decades.

Quizartinib is metabolized primarily via the CYP3A4 pathway, a factor with direct implications for drug interaction management in clinical use. The mean terminal elimination half-life ranges from approximately 16 to 30 hours following single-dose administration, supporting once-daily oral administration in clinical practice. Understanding these pharmacokinetic parameters is essential for formulary committees evaluating therapeutic protocols and potential drug-drug interactions in complex AML treatment regimens.

What Does FLT3-ITD Positive Mean for AML Patients?

FLT3-ITD refers to an internal tandem duplication within the juxtamembrane domain of the FMS-like tyrosine kinase 3 (FLT3) gene. This mutation results in constitutive kinase activation, driving unregulated proliferation of leukemic cells independent of normal growth factor signaling.

Epidemiology and Clinical Significance

FLT3-ITD mutations are among the most common molecular alterations in AML, occurring in approximately 25–30% of newly diagnosed adult AML cases. Their presence is recognized as an adverse prognostic marker, associated with higher relapse rates and shorter overall survival when treated with conventional chemotherapy regimens alone. Published clinical data demonstrate that FLT3-ITD-positive patients have significantly inferior outcomes compared to FLT3-wild-type patients when treated with standard 7+3 induction chemotherapy.

The clinical significance of FLT3-ITD positivity extends beyond prognosis — it defines a targetable oncogenic driver. Patients confirmed FLT3-ITD positive through validated molecular testing (typically polymerase chain reaction-based assays or next-generation sequencing panels) are candidates for FLT3-directed therapies such as quizartinib, making accurate mutation testing a prerequisite for appropriate therapeutic selection.

For procurement teams, this underscores the importance of ensuring Quizar availability aligns with institutional molecular diagnostic capabilities. Hospitals implementing FLT3-targeted therapy protocols require coordinated workflows between molecular pathology laboratories, hematology-oncology departments, and pharmacy services to ensure timely identification of eligible patients and appropriate drug access.

Approved Indication and Regulatory Status in Europe

Quizartinib (Vanflyta) is approved for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3-ITD positive. The regulatory milestone on record is FDA approval granted in July 2023, establishing quizartinib as a recognized therapeutic option for this molecularly defined AML population in the United States. This approval was based on the pivotal QuANTUM-First trial (NCT02668653), a randomized, double-blind, placebo-controlled Phase 3 study demonstrating improved overall survival in patients receiving quizartinib in combination with standard chemotherapy.

European Regulatory Considerations

European procurement teams and hospital importers should note that regulatory authorization status may differ by jurisdiction. As of the most recent publicly available information, buyers operating within European markets are advised to independently verify the current authorization status with the European Medicines Agency (EMA) or their respective national competent authority prior to procurement and clinical use.

We do not represent or fabricate regulatory approvals beyond those documented in official drug data. Procurement decisions should be made in consultation with institutional regulatory affairs specialists and in compliance with applicable national medicines legislation, including provisions for named patient access, compassionate use programs, or early access schemes where appropriate.

Quizar is the supplied brand available through our Bangladeshi pharmaceutical supply network. Procurement inquiries from European importers, hospital pharmacy departments, and international wholesalers should be directed to our team to confirm current availability and applicable import documentation requirements for their specific jurisdiction.

Dosage Forms and Administration Guidelines

Important: All dosing decisions for quizartinib must be made under the direction of a qualified physician experienced in the management of AML. The following information reflects the official drug data and is provided for formulary and procurement reference only.

Quizar is supplied as a 17.7 mg oral tablet. The specific dosing regimen is determined by the treating physician based on the indication, treatment phase, and individual patient factors, in strict accordance with the official prescribing information. This article does not state a dosing amount; all dosing questions should be directed to the prescribing information and the treating physician.

Administration Protocol

Administration instructions per official prescribing data include:

Administer orally with or without food
Take at approximately the same time each day to maintain consistent plasma concentrations
Swallow tablets whole — do not crush, split, or chew (to ensure proper pharmacokinetic profile)
If a dose is missed, follow the guidance provided in the prescribing information

Treatment Phases and Duration

The quizartinib treatment regimen typically consists of three phases:

Induction: Quizartinib in combination with standard induction chemotherapy (typically cytarabine and anthracycline)
Consolidation: Quizartinib in combination with consolidation chemotherapy cycles
Maintenance: Single-agent quizartinib for up to 3 years or until disease progression, unacceptable toxicity, or proceeding to HSCT

Pre-Transplant Cessation Requirement

For patients proceeding to hematopoietic stem cell transplantation (HSCT), quizartinib must be stopped 7 days before starting a conditioning regimen. This pre-HSCT cessation requirement is a critical clinical consideration that procurement and pharmacy teams should communicate clearly within institutional protocols. The 7-day washout period is designed to minimize potential drug-related toxicities during the conditioning phase while accounting for the drug’s elimination half-life.

Dose Modifications for Drug Interactions

When co-administered with strong CYP3A inhibitors (such as ketoconazole, itraconazole, clarithromycin, or ritonavir), a dose reduction is required; the specific adjustment should follow the prescribing information. Concomitant use with strong CYP3A inducers should be avoided, as these may significantly reduce quizartinib plasma concentrations and compromise efficacy.

Safety Profile: Key Risks and Monitoring Requirements

Quizartinib carries a clinically significant cardiac safety profile that requires structured monitoring protocols throughout the treatment course. The following safety information is derived from clinical trial data and official prescribing information.

QT Prolongation and Cardiac Risk

Quizartinib prolongs the QT interval in a concentration-related manner. Serious cardiac adverse events including torsades de pointes and cardiac arrest have been identified as serious risks in clinical studies. In the pivotal QuANTUM-First trial, QTc prolongation >500 msec occurred in approximately 11% of patients receiving quizartinib compared to 3% in the control arm.

Mandatory ECG Monitoring Protocol

Electrocardiogram (ECG) monitoring is mandatory at the following intervals:

Baseline: Prior to initiating therapy (to establish individual QTc baseline)
Induction and Consolidation: Weekly ECG monitoring throughout these intensive treatment phases
Maintenance: Weekly for at least the first month of maintenance therapy
Ongoing: Periodically thereafter throughout the treatment course, with increased frequency if QTc prolongation is detected
After dose modifications: Following any dose change or initiation of QT-prolonging concomitant medications

Electrolyte Management Requirements

Prior to administration and periodically during treatment, patients must be monitored for hypokalemia and hypomagnesemia, with deficiencies corrected before and during therapy. These electrolyte abnormalities independently increase the risk of QT prolongation and ventricular arrhythmias.

Quizartinib is contraindicated in patients with:

Severe hypokalemia (potassium <3.0 mEq/L despite supplementation)
Severe hypomagnesemia (magnesium <1.2 mg/dL despite supplementation)
Congenital long QT syndrome

Common Adverse Reactions

The most frequently reported adverse reactions (≥20% incidence) in clinical trials included:

Nausea
Fatigue and asthenia
Respiratory tract infections
Hypokalemia
Hypomagnesemia
Musculoskeletal pain
Diarrhea

Grade 3-4 laboratory abnormalities commonly observed include cytopenias (neutropenia, thrombocytopenia, anemia), which are expected in the context of intensive AML chemotherapy but may be exacerbated by quizartinib.

Embryo-Fetal Toxicity and Reproductive Considerations

Quizartinib carries a risk of embryo-fetal toxicity based on animal reproduction studies and its mechanism of action. Women of childbearing potential should be counseled regarding this risk and advised to use effective contraception during treatment and for at least 1 month after the final dose.

Breastfeeding is not recommended during treatment — patients should be advised not to breastfeed while receiving quizartinib and for at least 1 month after the final dose, as it is not known whether quizartinib or its metabolites are present in human milk.

Drug Interactions

As a CYP3A4 substrate, dose adjustments are required when co-administering strong CYP3A inhibitors; concomitant use with strong CYP3A inducers should be avoided. Additionally, caution is warranted when combining quizartinib with other QT-prolonging agents, as additive effects on QT interval may occur.

Procurement teams should ensure that institutional protocols include comprehensive medication reconciliation processes to identify potential drug interactions before initiating quizartinib therapy.

Side Effects

The following side effects have been identified in clinical studies and official prescribing information for quizartinib:

QT prolongation — quizartinib prolongs the QT interval; mandatory ECG monitoring is required throughout treatment.
Torsades de pointes — a serious ventricular arrhythmia associated with QT prolongation; patients must be monitored and electrolyte abnormalities corrected.
Cardiac arrest — identified as a serious risk in clinical studies; structured cardiac monitoring protocols are required.
Hypokalemia — low potassium levels have been commonly reported; electrolyte levels must be monitored and corrected before and during treatment. Quizartinib is contraindicated in severe hypokalemia.
Hypomagnesemia — low magnesium levels have been commonly reported; monitoring and correction are required. Quizartinib is contraindicated in severe hypomagnesemia.
Respiratory tract infection — among the most frequently reported adverse reactions in clinical trials.
Nausea — commonly reported adverse reaction observed in clinical trials.
Fatigue — commonly reported adverse reaction observed in clinical trials.

This list reflects adverse reactions from the structured source data. Additional adverse reactions, including cytopenias and embryo-fetal toxicity, are described in the Safety Profile section above. Patients should consult their treating physician regarding the full adverse reaction profile before initiating therapy.

Quizartinib vs. Other FLT3 Inhibitors: Market Context

Within the FLT3-targeted therapy landscape for AML, quizartinib is one of several agents developed to address FLT3-driven oncogenesis. Understanding the positioning of different FLT3 inhibitors is essential for formulary decision-making and therapeutic protocol development.

Comparative Clinical Positioning

Gilteritinib (Xospata) is another FLT3 inhibitor used in the AML setting, approved for relapsed or refractory FLT3-mutated AML based on the ADMIRAL trial. Its indication addresses patients who have failed initial therapy or experienced disease recurrence.

Midostaurin (Rydapt) was the first FLT3 inhibitor approved for newly diagnosed FLT3-mutated AML (both ITD and TKD mutations) in combination with standard chemotherapy, based on the RATIFY trial demonstrating improved overall survival.

Procurement teams and formulary committees evaluating FLT3 inhibitor options should note that quizartinib’s approved indication specifically addresses the newly diagnosed FLT3-ITD-positive AML population, which represents a distinct clinical positioning. The QuANTUM-First trial demonstrated that quizartinib, when added to standard chemotherapy, significantly improved overall survival compared to placebo plus chemotherapy in this specific patient population.

Clinical Differentiation Factors

Mutation specificity: Quizartinib is indicated specifically for FLT3-ITD mutations (not TKD mutations)
Treatment line: First-line therapy in combination with chemotherapy, followed by maintenance
Dosing convenience: Oral administration throughout all treatment phases
Maintenance duration: Extended single-agent maintenance for up to 3 years

Quizartinib — marketed globally under the brand name Vanflyta — has established its clinical profile through registration-enabling trial data in the newly diagnosed setting. For European procurement purposes, Quizar is the available manufactured brand supplied through our network, offering access to this therapeutic class from a Bangladeshi pharmaceutical manufacturer.

Sourcing Quizar (Quizartinib) for European Markets

We are a Bangladeshi pharmaceutical supplier specializing in the sourcing and distribution of Bangladeshi-manufactured oncology brands. Quizar, manufactured by Everest Pharmaceuticals Ltd., is the quizartinib brand available through our supply network for international B2B procurement.

Our Client Base

Our primary clients include:

European hospital pharmacy departments managing specialized oncology formularies
International pharmaceutical wholesalers serving multiple healthcare institutions
Named patient program coordinators facilitating individual patient access
Specialist oncology importers requiring reliable access to targeted therapy agents for FLT3-ITD-positive AML
Tender managers evaluating alternative supply sources for institutional procurement

Product Specifications

Quizar is available as 17.7 mg oral tablets in appropriate packaging configurations for institutional use. Each procurement inquiry should specify required quantities, delivery timelines, and destination country to enable accurate quotation and logistics planning.

Import Authorization and Regulatory Compliance

European buyers should note that import authorization, named patient or compassionate use documentation, and local regulatory compliance requirements will vary by country. Common documentation requirements may include:

Import license or authorization from the national competent authority
Named patient authorization or compassionate use approval (where applicable)
Certificate of pharmaceutical product (CPP) or equivalent manufacturing quality documentation
Prescriber documentation and patient-specific justification
Customs clearance documentation compliant with EU pharmaceutical import regulations

We recommend that procurement teams initiate early dialogue with our supply team to align on documentation requirements, lead times, and current availability. Our experienced logistics coordinators can provide guidance on typical import procedures for your specific jurisdiction, though ultimate regulatory responsibility rests with the importing institution.

Supply Chain Considerations

Lead times for Quizar procurement typically range from 4-8 weeks depending on destination country, current inventory levels, and documentation processing timelines. For urgent patient needs, expedited processing may be available subject to product availability and regulatory pathway feasibility.

We maintain quality assurance protocols aligned with WHO Good Distribution Practice guidelines and can provide supporting documentation including certificates of analysis, stability data, and manufacturing quality certifications upon request.

To inquire about Quizar availability, order quantities, and procurement logistics for your European market, please contact our team directly. We are equipped to support hospital procurement officers, tender managers, and wholesale distributors with the supply information needed to facilitate compliant importation of Bangladeshi-manufactured oncology products.

Frequently Asked Questions

What class of drug is quizartinib?

Quizartinib (Vanflyta) belongs to the tyrosine kinase inhibitor (TKI) class, specifically targeting the FLT3 receptor tyrosine kinase by binding to its ATP-binding domain and blocking FLT3-ITD-dependent cell proliferation. This positions it within the broader category of small molecule receptor tyrosine kinase inhibitors used in molecularly targeted oncology. It is indicated for adults with newly diagnosed FLT3-ITD-positive AML in combination with standard chemotherapy, followed by maintenance therapy.

The drug’s mechanism involves competitive inhibition of the ATP-binding site on the FLT3 receptor, preventing the constitutive kinase activation that drives leukemic cell proliferation in FLT3-ITD-positive disease. This targeted approach represents a significant advancement over traditional cytotoxic chemotherapy alone for this molecularly defined patient population.

What does FLT3-ITD positive mean for an AML patient?

FLT3-ITD positive means a patient’s leukemia cells carry an internal tandem duplication mutation in the FLT3 gene, causing constitutive, ligand-independent activation of the FLT3 receptor that drives uncontrolled proliferation of malignant cells. This mutation occurs in approximately 25–30% of newly diagnosed adult AML cases and is recognized as an adverse prognostic marker associated with higher relapse rates and shorter overall survival when treated with conventional chemotherapy alone.

Importantly, it also defines a targetable oncogenic driver, making patients candidates for FLT3-directed therapies such as quizartinib. Detection of FLT3-ITD status requires validated molecular testing (typically PCR-based assays or next-generation sequencing) and should be performed at diagnosis for all AML patients to guide appropriate therapeutic selection. The presence of this mutation fundamentally changes treatment strategy, as adding FLT3 inhibitors to standard chemotherapy has been shown to improve survival outcomes in this patient population.

What are the main side effects of quizartinib?

Key side effects of quizartinib include nausea, fatigue, respiratory tract infection, hypokalemia, and hypomagnesemia, alongside serious cardiac risks such as QT prolongation, torsades de pointes, and cardiac arrest. Embryo-fetal toxicity is also a recognized serious risk, and breastfeeding is not recommended during treatment.

Because of these risks, structured ECG monitoring is mandatory at baseline, weekly during induction and consolidation, weekly for at least the first month of maintenance, and periodically thereafter. Electrolyte monitoring and correction of deficiencies are required before and during treatment. The drug is contraindicated in patients with severe hypokalemia, severe hypomagnesemia, or congenital long QT syndrome.

Additional common adverse reactions include musculoskeletal pain, diarrhea, and cytopenias (which may be difficult to distinguish from underlying disease or chemotherapy effects). Patients require close monitoring throughout treatment, and dose modifications or treatment interruption may be necessary based on toxicity severity.

How is quizartinib administered, and are there any important stopping rules?

Quizartinib (Quizar) is supplied as a 17.7 mg tablet for oral administration, taken with or without food. Tablets must be swallowed whole and not crushed, split, or chewed. The specific dosing schedule is determined by the treating physician per the prescribing information.

The treatment regimen consists of three phases: (1) induction with standard chemotherapy, (2) consolidation with chemotherapy, and (3) single-agent maintenance for up to 3 years or until disease progression, unacceptable toxicity, or proceeding to HSCT.

Critical stopping rule: For patients proceeding to hematopoietic stem cell transplantation, quizartinib must be stopped 7 days before starting a conditioning regimen. This washout period accounts for the drug’s elimination half-life and minimizes potential drug-related toxicities during conditioning.

Dose adjustments may also be required when co-administering strong CYP3A inhibitors, and concomitant use with strong CYP3A inducers should be avoided as these may compromise efficacy.

Can your company source quizartinib for European hospital procurement?

Yes — we supply Quizar, the Bangladeshi-manufactured brand of quizartinib (Vanflyta) produced by Everest Pharmaceuticals Ltd., to European hospital pharmacy departments, international wholesalers, named patient program coordinators, and specialist oncology importers.

European buyers should be aware that import authorization and local regulatory compliance requirements vary by country. We recommend contacting our supply team early to align on documentation requirements, lead times (typically 4-8 weeks), and current availability. Our logistics coordinators can provide guidance on typical import procedures for your specific jurisdiction, though ultimate regulatory responsibility rests with the importing institution.

What documentation is typically required to import Quizar into European markets?

Import requirements for Quizar vary by European country and may include:

Import license or authorization from the national competent authority
Named patient authorization or compassionate use approval (where applicable for non-EMA-approved products)
Certificate of pharmaceutical product (CPP) or equivalent manufacturing quality documentation
Prescriber documentation and patient-specific justification
Customs clearance documentation compliant with EU pharmaceutical import regulations

Procurement teams are advised to independently verify current authorization requirements with their national authority or the EMA before initiating an order. Our supply team is equipped to support hospital procurement officers and tender managers in navigating the documentation process for compliant importation, providing necessary manufacturer documentation and logistics coordination.

For urgent patient needs, expedited processing may be available subject to product availability and regulatory pathway feasibility in your jurisdiction.

Access This Medicine Through oncosolution

We are a specialist oncology medicine supplier delivering to patients, pharmacies, hospitals, and distributors worldwide. Contact us for availability and sourcing support.

WhatsApp Us Message on Messenger

We do not publish prices online. All pricing is provided directly by our specialist supply team on request.

Medical Information Notice: This content is for informational purposes only and is based on official pharmaceutical product documentation. It does not constitute medical advice. Patients should consult their doctor or pharmacist before taking any medication.

Regulatory Disclaimer: Sourcing and distribution are subject to regional import regulations, quotas, and verified medical prescriptions where applicable. Pricing and availability are subject to change without notice.

Content Currency: This article was last reviewed and updated in June 2026. Regulatory approval statuses and product availability are subject to change; readers are advised to consult official regulatory databases for the most current information.